539 related articles for article (PubMed ID: 18543035)
21. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease.
Walker TR; Land ML; Kartashov A; Saslowsky TM; Lyerly DM; Boone JH; Rufo PA
J Pediatr Gastroenterol Nutr; 2007 Apr; 44(4):414-22. PubMed ID: 17414136
[TBL] [Abstract][Full Text] [Related]
22. Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome.
Sprakes MB; Hamlin PJ; Ford AC
Am J Gastroenterol; 2011 Jan; 106(1):166; author reply 166-7. PubMed ID: 21212757
[No Abstract] [Full Text] [Related]
23. Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature?
Caccaro R; D'Incà R; Pathak S; Sturniolo GC
Expert Rev Clin Immunol; 2012 Aug; 8(6):579-85. PubMed ID: 22992152
[TBL] [Abstract][Full Text] [Related]
24. Review article: biological activity markers in inflammatory bowel disease.
Desai D; Faubion WA; Sandborn WJ
Aliment Pharmacol Ther; 2007 Feb; 25(3):247-55. PubMed ID: 17217454
[TBL] [Abstract][Full Text] [Related]
25. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
Stragier E; Van Assche G
Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
[TBL] [Abstract][Full Text] [Related]
26. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
Shastri YM; Povse N; Schröder O; Stein J
Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
[No Abstract] [Full Text] [Related]
27. Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation.
Gearry R; Barclay M; Florkowski C; George P; Walmsley T
N Z Med J; 2005 May; 118(1214):U1444. PubMed ID: 15886739
[No Abstract] [Full Text] [Related]
28. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
29. [Fecal calprotectin: a diagnostic tool for inflammatory bowel disease].
Fraga M; Godat S; Nydegger A; Moradpour D; Schoepfer AM
Rev Med Suisse; 2012 Sep; 8(352):1669-70, 1672-3. PubMed ID: 22988727
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
[TBL] [Abstract][Full Text] [Related]
31. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
Mendoza JL; Abreu MT
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
[TBL] [Abstract][Full Text] [Related]
32. The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis.
Selimoğlu MA; Temel I; Yıldırım Ç; Özyaln F; Aktaş M; Karabiber H
Pediatr Crit Care Med; 2012 Jul; 13(4):452-4. PubMed ID: 22079952
[TBL] [Abstract][Full Text] [Related]
33. [Fecal calprotectin in the diagnosis of inflammatory bowel diseases].
Rodríguez-Moranta F; Lobatón T; Rodríguez-Alonso L; Guardiola J
Gastroenterol Hepatol; 2013; 36(6):400-6. PubMed ID: 23434080
[TBL] [Abstract][Full Text] [Related]
34. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
Sipponen T
Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
[TBL] [Abstract][Full Text] [Related]
35. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
Langhorst J; Boone J
Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
[TBL] [Abstract][Full Text] [Related]
36. Fecal calprotectin as a predictor of abnormal colonic histology.
Shitrit AB; Braverman D; Stankiewics H; Shitrit D; Peled N; Paz K
Dis Colon Rectum; 2007 Dec; 50(12):2188-93. PubMed ID: 17963005
[TBL] [Abstract][Full Text] [Related]
37. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
38. Is fecal calprotectin the next standard in inflammatory bowel disease activity tests?
Alic M
Am J Gastroenterol; 1999 Nov; 94(11):3370-1. PubMed ID: 10566749
[No Abstract] [Full Text] [Related]
39. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy.
von Roon AC; Karamountzos L; Purkayastha S; Reese GE; Darzi AW; Teare JP; Paraskeva P; Tekkis PP
Am J Gastroenterol; 2007 Apr; 102(4):803-13. PubMed ID: 17324124
[TBL] [Abstract][Full Text] [Related]
40. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
